The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio

Authors :: Terpos, Evangelos Delimpasi, Sosana Anargyrou, Konstantinos Baltathakis, Ioannis Kastritis, Efstathios Christoforidou, Anna Tsionos, Konstantinos Tsatalas, Konstantinos Nikiforakis, Emmanuel Dimopoulos, Meletios A others
Publication Year :: 2007

Tools